Stockwatch: Casualties From The War On Inversions
This article was originally published in Scrip
Executive Summary
In a surprise move last week, the US Treasury signalled its capacity to prevent any further inversion transactions and, with the public endorsement by President Obama, ended the proposed merger of Pfizer, Inc. and Allergan Plc that would have seen Pfizer relocate its tax jurisdiction to Ireland and access much of its offshore cash without a tax penalty.
You may also be interested in...
Stock Watch: Is Johnson & Johnson Edging Away From Pharma?
J&J’s Medtech division outshone pharma while recently launched innovative products contributed minimally: it is to be hoped investors’ reactions to the first set of big pharma Q1 results will not set the tempo for earnings season.
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.
Stock Watch: Pharma Businesses That Leave Consumer Behind
Healthcare conglomerates that divorce consumer, animal health and even generics businesses from their pure-play branded pharmaceutical groups could leave a less diversified and riskier sector in uncertain times. But the advantages are apparent.